In a presentation at Eyecelerator@AAO, Michael Coote discussed positive safety and efficacy data for PA5108, an ocular implant for glaucoma treatment. The phase 2 clinical trial showed statistically significant improvements in intraocular pressure (IOP) equivalent to topical latanoprost over 48 weeks. Coote, a principal investigator for PolyActiva, stated that PA5108 has met its requirements and will undergo further studies for over 12 months. The presentation took place at the AAO 2024 glaucoma/digital showcase in Chicago. The data suggests that PA5108 may be a promising treatment option for glaucoma patients.
Source link
Latanoprost implant for glaucoma shows improved IOP at 48 weeks
